Biocon Pharma Gets USFDA Approval for Generic Heart Failure Drug
Biocon Pharma gains USFDA approval for generic heart failure drug Sacubitril/Valsartan Tablets.
Biocon Pharma, a subsidiary of the biotechnology firm
Biocon, has secured approval from the US Food and Drug Administration (USFDA)
to market its generic version of Sacubitril/Valsartan Tablets. These tablets,
available in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, are used
to treat chronic heart failure in adults, helping to reduce the risk of death
and hospitalization. Additionally, the medication is approved for use in
pediatric patients aged one year and older.
This approval marks a significant expansion of Biocon's
portfolio, which focuses on complex, vertically integrated drug products.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion